Last reviewed · How we verify
Azo Gantrisin (sulfafurazole)
Azo Gantrisin (generic name: sulfafurazole) is a Sulfonamide Antimicrobial drug developed by Alra. It is currently FDA-approved (first approved 1971) for Acute otitis media, Chancroid, Chlamydia Cervicitis.
Azo Gantrisin, also known as sulfafurazole, is a sulfonamide antimicrobial drug developed by ALRA. It targets the endothelin-1 receptor and is used to treat various bacterial infections, including otitis media, chancroid, and meningococcal meningitis. The drug is a small molecule with a bioavailability of 96% and a half-life of 7.4 hours. It was FDA-approved in 1971 and is currently owned by ALRA. As a sulfonamide antimicrobial, Azo Gantrisin works by inhibiting bacterial growth and replication.
At a glance
| Generic name | sulfafurazole |
|---|---|
| Sponsor | Alra |
| Drug class | Sulfonamide Antimicrobial |
| Target | Endothelin-1 receptor |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1971 |
Approved indications
- Acute otitis media
- Chancroid
- Chlamydia Cervicitis
- Chlamydial conjunctivitis
- Falciparum malaria
- Haemophilus Influenzae Acute Otitis Media
- Infective otitis media
- Meningococcal meningitis
- Nocardiosis
- Pneumococcal Acute Otitis Media
- Trachoma
- Urethritis due to Chlamydia trachomatis
- Urinary tract infectious disease
Common side effects
Drug interactions
- methotrexate
- pralatrexate
- warfarin
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azo Gantrisin CI brief — competitive landscape report
- Azo Gantrisin updates RSS · CI watch RSS
- Alra portfolio CI
Frequently asked questions about Azo Gantrisin
What is Azo Gantrisin?
What is Azo Gantrisin used for?
Who makes Azo Gantrisin?
What is the generic name of Azo Gantrisin?
What drug class is Azo Gantrisin in?
When was Azo Gantrisin approved?
What development phase is Azo Gantrisin in?
What does Azo Gantrisin target?
Related
- Drug class: All Sulfonamide Antimicrobial drugs
- Target: All drugs targeting Endothelin-1 receptor
- Manufacturer: Alra — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Acute otitis media
- Indication: Drugs for Chancroid
- Indication: Drugs for Chlamydia Cervicitis